189574-46-7

Usage

Uses

Used in Food Industry:
Propanedioic acid, (3-methoxyphenoxy)-, dimethyl ester is used as a flavoring agent for enhancing the taste and aroma of various food products.
Used in Fragrance and Perfume Industry:
This chemical compound is used as an ingredient in fragrances and perfumes, contributing to the creation of unique and appealing scents.
Used in Pharmaceutical Industry:
Propanedioic acid, (3-methoxyphenoxy)-, dimethyl ester is utilized as an intermediate in the synthesis of pharmaceuticals and other organic compounds, playing a crucial role in the development of new medications.
It is important to handle this chemical with care, as it can cause irritation to the skin, eyes, and respiratory system, and may be harmful if ingested or inhaled.

Upstream product

• 2088-24-6 3-methoxyphenoxyacetic acid 
• 81720-20-9 methyl (3-methoxyphenoxy)acetate 
• 616-38-6 carbonic acid dimethyl ester 
• 150-19-6 O-methylresorcine 
• 28868-76-0 2-chlorodimethylmalonate 

Downstream Products

• 150727-91-6 C₁₁H₁₀N₂O₄ 
• 1393813-56-3 C₂₄H₂₃BrN₆O₆S 
• 1393813-62-1 C₂₀H₂₃BrN₆O₆S 
• 1392299-43-2 2-(3-methoxyphenoxy)propanedioic acid 

Relevant academic research and scientific papers

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation

Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.

Arylalkane-sulfonamides having endothelin-antagonist activity

The invention relates to novel aryl-alkane-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists

The synthesis and structure-activity relationships of a series of N-pyrimidinyl benzenesulfonamides as ETB selective antagonists are described. N-Isoxazolyl benzenesulfonamide 1a, previously reported, was selected as a lead compound, and isosteric replacement of the isoxazole ring of 1a with a pyrimidine ring led to the discovery of the highly potent ETB selective antagonist 6e with oral bioavailability. Modification of the terminal aldehyde group at the 6-position of the pyrimidine ring was investigated, and malonate 15b and acylhydrazone 16f were found to be equipped to aldehyde 6e. Compound 6e showed ETB antagonistic activity on in vivo evaluation. Copyright